Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Single-site, Dose-escalation Study Aiming to Evaluate the Efficacy and Safety of Anti-CD19 CAR-T Manufactured by OlyCAR Platform(OlyCAR-019) in the Treatment of Relapsed/ Refractory(r/r) B-Cell Malignancies

NCT05932173 is registered in ClinicalTrials.gov with 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China as lead sponsor.

NCT NCT05932173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05932173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Single-site, Dose-escalation Study Aiming to Evaluate the Efficacy and Safety of Anti-CD19 CAR-T Manufactured by OlyCAR Platform(OlyCAR-019) in the Treatment of Relapsed/ Refractory(r/r) B-Cell Malignancies
Lead sponsor
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 1, 2023
Completion date
June 30, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell leukemia, b-cell lymphoma, b-cell tumors